The two companies said they will collaborate on clinical trials for medications for treating nonalcoholic steatohepatitis (NASH).
"The intended clinical trial will be a proof of concept study," according to a press release from Gilead.
It also explains the potential severity of the disease: "If left untreated, individuals living with NASH may face serious consequences, including end-stage liver disease, liver cancer and the need for liver transplantation, and are at a significantly higher risk of liver-related mortality."
The company statement bills Gilead and Novo Nordisk as leaders in molecular science and clinical expertise, respectively.
"[Together] we aim to develop innovative, new and effective combination therapies to help people with NASH," said Mads Krogsgaard Thomsen, chief science officer at Novo Nordisk, in a statement.